Detailed results from the IMpower133 study suggest Roche (ROG: SIX) is poised to steal a march on immuno-oncology rivals in the relatively small population of small cell lung cancer patients.
Fleshing out headline data released earlier in the year, Roche says a drug cocktail of Tecentriq (atezolizumab) plus carboplatin and etoposide beat chemotherapy alone, with overall survival rates of 12.3 months against 10.3 months.
Earlier this month, US rival Merck & Co (NYSE: MRK) won approval from European regulators for Keytruda (pembrolizumab) plus chemo in the larger, more lucrative, non-small cell lung cancer indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze